NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
According to the brokerage firm Motilal Oswal Sun Pharmaceutical Industries Ltd. remains on track to-
- expand its innovative medicine portfolio through enhanced marketing efforts on new launches, increasing the prescriber base
- the prescription rate for existing products.
Further, improved industry-level growth and strong brand franchise support healthy growth for Sun Pharma.
Currency tailwinds would be a favorable growth driver for Sun Pharma's revenue. These benefits would be partially offset by price erosion in the US generics segment.
Accordingly, we build in an 11% earnings CAGR over FY26-28.
Motilal Oswal maintains its earnings estimates for FY27/FY28 and values Sun Pharma at 38 times 12-month forward earnings to arrive at a target price of Rs 2,310.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
